This is an old revision of this page, as edited by WikitanvirBot (talk | contribs) at 20:22, 28 November 2011 (r2.7.1) (Robot: Adding ru:Тримебутин). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 20:22, 28 November 2011 by WikitanvirBot (talk | contribs) (r2.7.1) (Robot: Adding ru:Тримебутин)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) Pharmaceutical compound | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| ATC code | |
| Identifiers | |
IUPAC name
| |
| CAS Number | |
| PubChem CID | |
| UNII | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.049.354  |
| Chemical and physical data | |
| Formula | C22H29NO5 |
| Molar mass | 387.47 g/mol g·mol |
| (verify) | |
Trimebutine is a drug with antimuscarinic and weak mu opioid agonist effects. The maleic acid salt of trimebutine is marketed under the trademark of Debridat, Recutin, Polybutin, or Modulon for treatment of irritable bowel syndrome and other gastrointestinal disorders. The major product from drug metabolism of trimebutine in human beings is nor-trimebutine, which comes from removal of one of the methyl groups attached to nitrogen. Both Trimebutine and its metabolite are commercially available.
References
- Kaneto H, Takahashi M, Watanabe J. The opioid receptor selectivity for trimebutine in isolated tissues experiments and receptor binding studies. Journal of Pharmacobiodynamics. 1990 Jul;13(7):448-53. PMID 1963196
- Ok Hwa Jhee, Yun Sik Lee, Leslie M. Shaw, Yong Cheol Jeon, Min Ho Lee, Seung Hoon Lee and Ju Seop Kang The Pharmacokinetic and bioequivalence evaluation of two formulations of 100 mg trimebutine maleate (Recutin and Polybutin) in healthy male volunteers using the LC–MS/MS method. Clinica Chimica Acta. 2007 Jan;375(1-2):69-75. PMID 16854404
- F.J. Roman, S. Lanet, J. Hamon, G. Brunelle, A. Maurin, P. Champeroux, S. Richard, N. Alessandri, and M. Gola Pharmacological Properties of Trimebutine and N-Monodesmethyltrimebutine. The Journal of Pharmacology and Experimental Therapeutics 1999;289:1391–1397. PMID 10336531
| Drugs for functional gastrointestinal disorders (A03) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Drugs for functional bowel disorders |
| ||||||||||||
| Belladonna and derivatives (antimuscarinics) |
| ||||||||||||
| Propulsives | |||||||||||||
 | This drug article relating to the gastrointestinal system is a stub. You can help Misplaced Pages by expanding it. |